Herlev, Denmark, November 16, 2026
Roche Diagnostics and Nordic Bioscience have reached a new milestone in their biomarker collaboration with the availability of an Endotrophin (ETP) research prototype assay on Roche’s cobas® e 801 analyzers at Nordic Bioscience’s Clinical Laboratory Improvement Amendments (CLIA) laboratory in Herlev, Denmark. The assay is designed to quantify intact Endotrophin, a 77-amino-acid signalling pro-peptide released during the formation of type VI collagen. This protein fragment is associated with fibrosis, inflammation, and adverse outcomes across cardiovascular, kidney, and metabolic diseases. The development expands the companies’ work on biomarkers that may help researchers understand fibro-inflammatory disease processes and improve patient stratification in clinical studies. Endotrophin is the second biomarker from the Roche and Nordic Bioscience collaboration to reach the Roche platform, following Elecsys® PRO-C3, which is available as a CE-marked test. The new prototype assay provides researchers with an additional analytical tool for investigating Endotrophin levels and their relationship with disease progression. Its availability also supports further research into the potential role of this biomarker in cardiovascular and chronic kidney disease. The companies’ announcement highlights the growing importance of biomarker technologies in precision medicine, clinical research, and the development of targeted therapies.
Endotrophin Assay Targets Fibrosis and Inflammation
The Endotrophin assay uses a sandwich immunoassay format to measure the intact 77-amino-acid hormone. Endotrophin is released during the formation of type VI collagen, an extracellular matrix protein involved in tissue structure and cellular interactions. Changes in extracellular matrix activity are closely connected with tissue remodelling, inflammation, and fibrosis. These processes contribute to the development and progression of several chronic conditions, including cardiovascular disease, chronic kidney disease, and metabolic disorders. By measuring Endotrophin specifically, researchers may gain additional information about fibro-inflammatory activity beyond conventional clinical measurements. According to Nordic Bioscience, Endotrophin has already been measured in more than 50,000 patients with cardio-kidney-metabolic diseases. Elevated levels have been associated with mortality and adverse outcomes in heart failure with preserved ejection fraction (HFpEF). In chronic kidney disease, higher Endotrophin levels have been associated with increasing disease activity and future decline in estimated glomerular filtration rate (eGFR). These observations support continued investigation of the biomarker as a potential tool for disease-risk assessment and clinical-trial enrichment. However, the prototype assay’s availability does not itself establish its clinical utility as a routine diagnostic test.
Research Evidence Supports Cardiovascular and Kidney Applications
The companies highlighted research suggesting that Endotrophin may provide information about fibro-inflammatory risk beyond established cardiovascular indicators, including PREVENT and NT-proBNP. A 2026 study presented at the American Heart Association Scientific Sessions reported that Endotrophin captured additional fibro-inflammatory risk in adults with obesity and HFpEF. The U.S. Food and Drug Administration has also issued a letter of support for continued research into Endotrophin as a clinical-trial enrichment tool in HFpEF. This support should not be interpreted as FDA approval or authorization of the assay for clinical diagnosis. In chronic kidney disease, research has associated elevated Endotrophin with greater disease activity, while changes in its levels have been reported to track changes in kidney function. Beyond its potential role as a biomarker, scientific investigations have explored its biological involvement in disease mechanisms. Mendelian randomization studies have linked Endotrophin with coronary artery disease, while experimental knockout models have reported protection against kidney fibrosis and loss of kidney function. Researchers have also identified CD44 as the Endotrophin receptor, providing further insight into its possible biological activity. These findings create opportunities for further investigation into both biomarker applications and potential therapeutic targets, although additional studies are needed to establish clinical relevance.
Roche and Nordic Bioscience Expand Biomarker Collaboration
The introduction of the Endotrophin research prototype on Roche’s cobas® e 801 platform represents another step in the companies’ collaboration to develop and evaluate biomarkers for clinical research. Their earlier collaboration brought Elecsys® PRO-C3 to the Roche platform as a CE-marked test. Nordic Bioscience specialises in extracellular matrix biomarker development and uses its neoepitope technology to study biological processes associated with chronic disease. Roche contributes its established diagnostic analyser platform and expertise in laboratory testing technologies. Making the Endotrophin prototype available at Nordic Bioscience’s CLIA laboratory provides a research setting for further evaluation of the assay and its applications. The assay is currently described as a research prototype, and its availability should not be confused with commercial launch, routine diagnostic availability, or regulatory clearance for clinical use. Overall, the collaboration highlights the growing role of specialised biomarker assays in investigating complex diseases and supporting the development of precision-medicine approaches. Further clinical validation will be important to determine how Endotrophin measurement can be incorporated into patient assessment, clinical-trial design, and future diagnostic strategies.
Source: Roche Diagnostics, Nordic Bioscience press release



